RUXOLITINIB

Information current as at: 1 June 2026

PBAC meeting date: September 2022
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Jakavi®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Novartis Pharmaceuticals Australia Pty Limited
Condition/indication:
(therapeutic use)
  • Graft versus host disease
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to PBS listing (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
September 2022 PBAC meeting
Opportunity for consumer comment:
Open 30/03/2022 and close 25/05/2022 (see PBS Website)
PBAC meeting:
Held on 02/09/2022
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – September 2022
Case ID
a615
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19